Your browser is no longer supported. Please, upgrade your browser.
Abiomed, Inc.
IndexS&P 500 P/E92.44 EPS (ttm)3.25 Insider Own1.40% Shs Outstand45.44M Perf Week-7.78%
Market Cap14.21B Forward P/E59.65 EPS next Y5.04 Insider Trans-15.36% Shs Float44.56M Perf Month-16.03%
Income149.20M PEG9.11 EPS next Q1.34 Inst Own92.80% Short Float2.24% Perf Quarter-19.34%
Sales973.60M P/S14.60 EPS this Y11.40% Inst Trans-1.09% Short Ratio4.55 Perf Half Y3.26%
Book/sh30.47 P/B9.87 EPS next Y19.63% ROA10.10% Target Price387.33 Perf Year12.66%
Cash/sh13.76 P/C21.85 EPS next 5Y10.15% ROE11.30% 52W Range254.41 - 387.40 Perf YTD-7.27%
Dividend- P/FCF60.92 EPS past 5Y42.20% ROI12.50% 52W High-22.40% Beta1.27
Dividend %- Quick Ratio6.90 Sales past 5Y20.80% Gross Margin81.90% 52W Low18.17% ATR14.29
Employees1725 Current Ratio7.60 Sales Q/Q18.30% Oper. Margin14.90% RSI (14)30.95 Volatility4.76% 3.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.90% Profit Margin15.30% Rel Volume1.23 Prev Close312.44
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout0.00% Avg Volume219.27K Price300.63
Recom2.40 SMA20-11.99% SMA50-11.94% SMA200-7.48% Volume270,143 Change-3.78%
Jun-18-21Initiated Deutsche Bank Buy $360
Apr-27-20Downgrade SVB Leerink Outperform → Mkt Perform $175
Feb-12-20Downgrade Morgan Stanley Equal-Weight → Underweight $165
Feb-06-20Resumed BTIG Research Neutral
Oct-29-19Downgrade Raymond James Outperform → Mkt Perform
Aug-02-19Downgrade Morgan Stanley Overweight → Equal-Weight $325 → $215
Aug-02-19Downgrade Guggenheim Buy → Neutral
Aug-01-19Downgrade BTIG Research Buy → Neutral
Nov-07-18Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-02-18Upgrade BTIG Research Neutral → Buy
Jun-22-18Reiterated Piper Jaffray Overweight $360 → $480
Apr-04-18Initiated Goldman Buy $332
Jan-19-18Reiterated Leerink Partners Outperform $200 → $265
Oct-16-17Downgrade BTIG Research Buy → Neutral
Sep-29-17Initiated SunTrust Buy $195
Jun-08-17Resumed William Blair Outperform
Apr-06-17Upgrade Piper Jaffray Neutral → Overweight
Dec-07-16Initiated Guggenheim Buy
Oct-30-15Upgrade Raymond James Mkt Perform → Outperform
Aug-18-15Initiated Sterne Agee CRT Buy $130
Nov-18-21 07:00AM  
Nov-04-21 08:05AM  
Nov-03-21 08:02AM  
Nov-01-21 07:58AM  
Oct-28-21 02:00PM  
Oct-25-21 03:27PM  
Oct-22-21 10:54AM  
Oct-21-21 03:03PM  
Oct-07-21 07:00AM  
Oct-06-21 03:21AM  
Sep-20-21 09:59AM  
Sep-15-21 06:55AM  
Sep-13-21 06:30AM  
Sep-03-21 11:31AM  
Aug-19-21 10:55AM  
Aug-18-21 08:02AM  
Aug-13-21 11:48AM  
Aug-05-21 01:01PM  
Aug-04-21 06:55PM  
Jul-29-21 03:05PM  
Jul-15-21 07:00AM  
Jul-13-21 09:22AM  
Jul-03-21 07:07AM  
Jun-30-21 09:06AM  
Jun-29-21 08:03AM  
Jun-24-21 04:48PM  
Jun-22-21 08:29AM  
Jun-15-21 01:14AM  
Jun-03-21 10:40AM  
Jun-01-21 08:03AM  
May-25-21 07:00AM  
May-16-21 03:09AM  
May-11-21 06:40AM  
May-04-21 09:16AM  
Apr-29-21 01:43PM  
Apr-28-21 03:57PM  
Apr-25-21 04:48PM  
Apr-23-21 11:25AM  
Apr-22-21 12:33PM  
Apr-16-21 02:23AM  
Apr-15-21 08:03AM  
Apr-10-21 06:00AM  
Apr-08-21 07:00AM  
Apr-03-21 06:40AM  
Apr-01-21 06:57AM  
Mar-31-21 07:17AM  
Mar-21-21 07:37AM  
Mar-11-21 11:40AM  
Mar-10-21 06:00AM  
Mar-04-21 09:00AM  
Mar-01-21 11:26PM  
Feb-27-21 11:30AM  
Feb-17-21 08:03AM  
Feb-11-21 11:47AM  
Feb-04-21 07:47AM  
Feb-02-21 06:20AM  
Feb-01-21 10:51AM  
Jan-31-21 01:04AM  
Jan-29-21 09:36AM  
Jan-28-21 01:51PM  
Jan-26-21 12:20PM  
Jan-14-21 07:00AM  
Jan-07-21 09:13AM  
Jan-05-21 11:40PM  
Dec-29-20 01:29PM  
Dec-23-20 06:53AM  
Dec-21-20 08:05AM  
Dec-15-20 08:03AM  
Dec-06-20 11:29PM  
Nov-25-20 07:00AM  
Nov-18-20 06:36AM  
Nov-11-20 07:00AM  
Nov-07-20 07:07AM  
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUTTER MARTIN PDirectorNov 18Sale338.5915,0005,078,787138,390Nov 18 04:45 PM
SUTTER MARTIN PDirectorNov 17Sale344.953,7501,293,573153,390Nov 18 04:45 PM
SUTTER MARTIN PDirectorNov 16Sale351.853,7501,319,448157,140Nov 18 04:45 PM
MINOGUE MICHAEL RChairman, President, CEOAug 23Option Exercise23.153,49280,840215,127Aug 25 04:37 PM
MINOGUE MICHAEL RChairman, President, CEOAug 23Sale350.003,4921,222,200211,635Aug 25 04:37 PM
THOMAS PAULDirectorAug 18Sale330.77663219,3016,908Aug 19 04:17 PM
SUTTER MARTIN PDirectorAug 18Sale332.903,7501,248,373161,890Aug 19 04:16 PM
SUTTER MARTIN PDirectorAug 17Sale326.733,7501,225,250165,640Aug 19 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOAug 09Option Exercise23.157,037162,907218,672Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 09Sale350.007,0372,462,950211,635Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 06Option Exercise23.1524,471566,504236,106Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 06Sale350.0024,4718,564,850211,635Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 05Option Exercise23.1525,000578,750236,635Aug 06 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOAug 05Sale341.1825,0008,529,582211,635Aug 06 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOJun 21Option Exercise23.1525,000578,750236,635Jun 23 04:05 PM
MINOGUE MICHAEL RChairman, President, CEOJun 21Sale325.3525,0008,133,702211,635Jun 23 04:05 PM
SUTTER MARTIN PDirectorMay 19Sale267.443,7501,002,900169,010May 20 04:28 PM
SUTTER MARTIN PDirectorMay 18Sale266.723,7501,000,200172,760May 20 04:28 PM
SUTTER MARTIN PDirectorFeb 17Sale314.013,7501,177,538176,510Feb 18 04:11 PM
SUTTER MARTIN PDirectorFeb 16Sale330.673,7501,240,012180,260Feb 18 04:11 PM
PUHY DOROTHY EDirectorFeb 01Sale349.475,0001,747,3472,869Feb 03 05:03 PM
Greenfield Andrew JVP, Chief Commercial OfficerJan 28Option Exercise66.255,000331,25036,930Feb 01 05:14 PM
Greenfield Andrew JVP, Chief Commercial OfficerJan 28Sale366.005,0001,830,00031,930Feb 01 05:14 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 29Sale321.005,0001,605,00026,930Dec 31 04:03 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 22Sale296.671,682498,99731,930Dec 23 04:04 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 21Sale295.635,4741,618,27933,612Dec 23 04:04 PM